CA2333901A1 - Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments - Google Patents

Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments Download PDF

Info

Publication number
CA2333901A1
CA2333901A1 CA002333901A CA2333901A CA2333901A1 CA 2333901 A1 CA2333901 A1 CA 2333901A1 CA 002333901 A CA002333901 A CA 002333901A CA 2333901 A CA2333901 A CA 2333901A CA 2333901 A1 CA2333901 A1 CA 2333901A1
Authority
CA
Canada
Prior art keywords
group
composition
formulation
receptor
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002333901A
Other languages
English (en)
French (fr)
Inventor
Jonathan W. Nyce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East Carolina University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2333901A1 publication Critical patent/CA2333901A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002333901A 1998-08-03 1999-08-03 Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments Abandoned CA2333901A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9521298P 1998-08-03 1998-08-03
US60/095,212 1998-08-03
PCT/US1999/017712 WO2000009525A2 (en) 1998-08-03 1999-08-03 Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments

Publications (1)

Publication Number Publication Date
CA2333901A1 true CA2333901A1 (en) 2000-02-24

Family

ID=22250687

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002333901A Abandoned CA2333901A1 (en) 1998-08-03 1999-08-03 Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments

Country Status (6)

Country Link
EP (1) EP1102786A4 (de)
CN (1) CN1317009A (de)
AU (1) AU5337499A (de)
CA (1) CA2333901A1 (de)
HK (1) HK1042706A1 (de)
WO (1) WO2000009525A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825174B2 (en) 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US7034007B1 (en) 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
EP1165783A4 (de) * 1999-03-26 2002-09-11 Human Genome Sciences Inc 47 menschliche, sekretierte proteine
CA2368442A1 (en) * 1999-03-26 2000-10-05 Craig A. Rosen 48 human secreted proteins
WO2000062736A2 (en) * 1999-04-06 2000-10-26 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion
US6489151B1 (en) * 2000-03-27 2002-12-03 The Research Foundation Of State University Of New York Biologically active alternative form of the IKKα IκB kinase
DE10019252A1 (de) * 2000-04-18 2001-10-31 Klaus Karl Degitz Polydesoxyribonukleotide zur Hemmung der ICAM-1-Genexpression
DE10049549A1 (de) 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
ES2301659T3 (es) * 2001-07-06 2008-07-01 Topigen Pharmaceuticals Inc. Metodos para aumentar la eficacia in vivo de oligonucleotidos e inhibir la inflamacion en mamiferos.
JP2005522519A (ja) * 2002-04-05 2005-07-28 ユニヴァーシティ コート オブ ザ ユニヴァーシティ オブ エディンバラ 精神分裂病関連遺伝子
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
CN1322899C (zh) * 2004-02-11 2007-06-27 中国科学院上海生命科学研究院 抗肝癌基因药物组合物、小分子干扰rna及其筛选方法
RU2416412C2 (ru) 2004-10-29 2011-04-20 Топиджен Фармасьютикалз Инк. Антисмысловые олигонуклеотиды для лечения аллергии и пролиферации неопластических клеток
MX2008002101A (es) 2005-08-12 2008-04-19 Schering Corp Fusiones de la proteina-1 quimiotactica de monocito.
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
US10017762B2 (en) * 2010-11-24 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
CN103635575B (zh) * 2011-06-15 2019-03-01 盖立复治疗公司 用于测定人免疫缺陷病毒（hiv）的方法、组合物和试剂盒
CN102866153B (zh) * 2012-09-29 2014-08-13 郑州安图生物工程股份有限公司 前列腺炎联合检测试剂盒
RU2015138544A (ru) * 2013-03-11 2017-04-18 Юниверсити Оф Норс Керолайна Эт Чапел Хилл Композиции и способы целенаправленного воздействия на О-связанную N-ацетилглюкозаминтрансферазу и стимулирования заживления ран
EP4237436A2 (de) * 2020-10-29 2023-09-06 Mariano A. Garcia-Blanco Lösliche interleukin-7-rezeptor (sil7r)-modulierende therapie zur behandlung von krebs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3222793A (en) * 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6498147B2 (en) * 1992-05-22 2002-12-24 The Scripps Research Institute Suppression of nuclear factor-κb dependent processes using oligonucleotides
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5932557A (en) * 1997-08-12 1999-08-03 Mustafa; S. Jamal Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments
EP1080225A4 (de) * 1998-05-21 2004-02-04 Isis Pharmaceuticals Inc Zusammensetzungen und methoden zur pulmonalen verabreichung von nukleinsäuren

Also Published As

Publication number Publication date
EP1102786A4 (de) 2002-03-06
AU5337499A (en) 2000-03-06
WO2000009525A3 (en) 2000-05-18
HK1042706A1 (zh) 2002-08-23
CN1317009A (zh) 2001-10-10
WO2000009525A2 (en) 2000-02-24
EP1102786A2 (de) 2001-05-30

Similar Documents

Publication Publication Date Title
AU2021204244B2 (en) Conjugated antisense compounds and their use
KR102149571B1 (ko) 성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법
AU2018203564A1 (en) Antisense modulation of gccr expression
AU2016376191A1 (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
AU2016364667A1 (en) Materials and methods for treatment of Alpha-1 antitrypsin deficiency
KR102236784B1 (ko) 성장 호르몬 수용체의 조절인자
CA2333901A1 (en) Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
AU2021203300B2 (en) Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
CN1330513A (zh) 低腺苷反义寡核苷酸、组合物、试剂盒及与支气管紧缩、肺炎、过敏及表面活性剂缺失相关的通气途径疾病的治疗方法
KR20210138587A (ko) 개선된 면역요법을 위한 조합 유전자 표적
KR20150013507A (ko) 아포지질단백질 (a) 발현을 조절하는 방법들 및 조성물들
KR20220012230A (ko) 스플라이싱 및 번역을 조절하기 위한 방법 및 조성물
KR20230034198A (ko) 종양 침윤 림프구의 활성화 및 확장 방법
DK2809400T3 (en) COMBINATION THERAPY INCLUDING A GROWTH HORMON VARIANT AND AN OIGONUCLEOTIDE BINDING TO THE GROWTH HORMON RECEPTOR
KR20210144822A (ko) Ube3a-ats를 조절하기 위한 화합물 및 방법
KR20230005933A (ko) Atxn1을 조정하는 화합물 및 방법
CN111344408A (zh) 用于调控fndc3b表达的寡核苷酸
MXPA01000971A (es) Agente composicion, estuche y tratamientos que emplean un oligonucleotido con bajo contenido de adenosina
AU2021202471A1 (en) Cancer therapeutic methods
TW202305132A (zh) 用於抑制α-突觸核蛋白表達之反義寡核苷酸
TW202424191A (zh) 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
NZ715825B2 (en) Combination therapy for treatment of acromegaly

Legal Events

Date Code Title Description
FZDE Dead